Zydus Lifesciences moves higher on getting USFDA’s nod to initiate Phase II clinical study of ‘ZYIL1’ in patients

Zydus Lifesciences is currently trading at Rs. 674.90, up by 28.70 points or 4.44% from its previous closing of Rs. 646.20 on the BSE.

The scrip opened at Rs. 650.40 and has touched a high and low of Rs. 677.25 and Rs. 650.40 respectively. So far 164482 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 677.25 on 18-Dec-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022.

Last one week high and low of the scrip stood at Rs. 677.25 and Rs. 632.05 respectively. The current market cap of the company is Rs. 68070.73 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.95% and 7.07% respectively.

ZYIL1 is a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation

Zydus Lifesciences has received permission from the United States Food and Drug Administration (USFDA), to initiate the Phase II clinical study of NLRP3 inhibitor ‘ZYIL1’ in patients with Parkinson’s disease. Parkinson’s is a devastating disease with patients steadily losing the control on movements leading to unintended or uncontrollable movements, such as shaking, stiffness and difficulty with balance and co-ordination. It is estimated that there are more than 8.5 million people in the world suffering from Parkinson’s disease, with 1 million suffering from the disease in the US. Each year 90,000 new cases of Parkinson’s disease are reported in the US. Analysts estimate that the treatment costs of Parkinson’s disease amounts to almost $52 billion every year, and by 2037 this disease is estimated to touch $80 billion every year.

ZYIL1 is a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation. ZYIL1 was found distributed in the brain & CSF of various nonclinical species including mice, rats and non-human primates. The efficacy of ZYIL1 has been established in a number of validated pre-clinical models of neuro-inflammation and Parkinson’s disease.

ZYIL1, has demonstrated desirable ADME profile, with good safety margin. In phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers. The Phase 2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Parkinson’s Disease. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.